French national health insurance information system and the permanent beneficiaries sample.
暂无分享,去创建一个
A. Weill | P. Tuppin | P. Ricordeau | A. Weill | P. Ricordeau | P. Tuppin | L. de Roquefeuil | Y. Merlière | Y. Merlière | Alain Weill | A. Weill | L. de Roquefeuil | L. D. Roquefeuil
[1] L. Roquefeuil,et al. L'échantillon généraliste de bénéficiaires : représentativité, portée et limites , 2009 .
[2] F. Carbonnel,et al. Fine‐scale geographic variations of inflammatory bowel disease in France: Correlation with socioeconomic and house equipment variables , 2010, Inflammatory bowel diseases.
[3] A. Weill,et al. Primary Health Care Use and Reasons for Hospital Admissions in Dementia Patients in France: Database Study for 2007 , 2009, Dementia and Geriatric Cognitive Disorders.
[4] J. Dartigues,et al. BMC Geriatrics BioMed Central , 2009 .
[5] J Raftery,et al. Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation. , 2005, Health technology assessment.
[6] Bruce M Psaty,et al. Benefits and risks of drug treatments: how to combine the best evidence on benefits with the best data about adverse effects. , 2008, JAMA.
[7] A. Weill,et al. Changes by age in breast cancer incidence, mammography screening and hormone therapy use in France from 2000 to 2006. , 2009, Bulletin du cancer.
[8] B. Salanave,et al. Prevalence and treatment of diabetes in France: trends between 2000 and 2005. , 2008, Diabetes & metabolism.
[9] V. Jooste,et al. Cost of care of colorectal cancers according to health care patterns and stage at diagnosis in France , 2008, The European Journal of Health Economics.
[10] P. Verger,et al. Impact de l’estimation de la population affiliée à l’assurance-maladie sur le calcul de la prévalence pharmacologique du diabète à l’échelle régionale et territoriale , 2009 .
[11] B. Bégaud,et al. Pharmacoepidemiological research using French reimbursement databases: yes we can! , 2010, Pharmacoepidemiology and drug safety.
[12] N. Danchin,et al. Combined secondary prevention after hospitalization for myocardial infarction in France: analysis from a large administrative database. , 2009, Archives of cardiovascular diseases.
[13] J. Avorn,et al. A review of uses of health care utilization databases for epidemiologic research on therapeutics. , 2005, Journal of clinical epidemiology.
[14] P. Verger,et al. [Impact of the estimation of the medically insured population on the pharmacological prevalence of diabetes at the regional and small area level]. , 2009, Revue d'epidemiologie et de sante publique.
[15] A. Fagot-Campagna,et al. Self-monitoring of blood glucose in people with type 1 and type 2 diabetes living in France: the Entred study 2001. , 2008, Diabetes & metabolism.
[16] F A Allaert,et al. FOIN: a nominative information occultation function. , 1997, Studies in health technology and informatics.
[17] J. Dartigues,et al. Comparison of health insurance claims and patient interviews in assessing drug use: data from the Three‐City (3C) Study , 2009, Pharmacoepidemiology and drug safety.
[18] J Raftery,et al. Potential use of routine databases in health technology assessment. , 2005, Health technology assessment.
[19] V. Rodwin. The health care system under French national health insurance: lessons for health reform in the United States. , 2003, American journal of public health.
[20] Gerald F Riley,et al. Administrative and Claims Records as Sources of Health Care Cost Data , 2009, Medical care.
[21] J. Benichou,et al. Impact of Prescriber Nonresponse on Patient Representativeness , 2008, Epidemiology.
[22] P. Böelle,et al. Significant Reduction of Antibiotic Use in the Community after a Nationwide Campaign in France, 2002–2007 , 2009, PLoS medicine.
[23] M. Goldberg. [Administrative data bases: could they be useful for epidemiology?]. , 2006, Revue d'epidemiologie et de sante publique.